Health · Medical Research · 6 hrs ago
Sacituzumab tirumotecan cut death risk in advanced endometrial cancer trial
A global Phase 3 trial found sacituzumab tirumotecan reduced the risk of death by 32% in women with advanced or recurrent endometrial cancer.
The 776 participants in the TroFuse-005 study had already received chemotherapy and immunotherapy, and their cancer had progressed.
The drug extended median overall survival by seven months compared with chemotherapy.
It also reduced the risk of the cancer worsening by 41%.
Sacituzumab tirumotecan is a targeted medicine developed by Merck and China's Kelun-Biotech.
The results could help change treatment for patients whose disease progresses after those earlier therapies.
Merck is running 18 global Phase 3 studies of the drug to support possible approvals outside China.
Sacituzumab tirumotecan reduced the risk of death by 32% in a Phase 3 study of advanced or recurrent endometrial cancer.
The study also found a 41% reduction in the risk of disease progression and a seven-month increase in median overall survival.
It involved 776 women whose cancer had progressed after chemotherapy and immunotherapy.
Results were presented at the European Society for Medical Oncology congress and published simultaneously in The Lancet.
Merck and China’s Kelun-Biotech developed the drug, also known as sac-TMT.
- Who
- Merck and China’s Kelun-Biotech developed sacituzumab tirumotecan. The study involved 776 women with endometrial cancer.
- What
- A Phase 3 study found the drug reduced the risk of death by 32% and the risk of disease progression by 41%.
- When
- Results were presented Monday, October 26, 2026.
- Where
- At the European Society for Medical Oncology congress; the trial involved 242 centres in 31 countries.
- Why
- The study evaluated the drug in patients with advanced or recurrent endometrial cancer that progressed after chemotherapy and immunotherapy.
This story does not have two clearly opposing sides.
The Phase 3 TroFuse-005 study evaluated sacituzumab tirumotecan in patients whose cancer had progressed after chemotherapy and immunotherapy.
Study results were presented at the European Society for Medical Oncology congress and published simultaneously in The Lancet.
- Drug
- Sacituzumab tirumotecan (sac-TMT)
- Death risk reduction
- 32%
- Disease progression risk reduction
- 41%
- Median overall survival increase
- 7 months
- Study size
- 776 women
- Study reach
- 242 centres in 31 countries
3 sources
What people are saying
Sac-TMT is the first anti-TROP2 antibody-drug conjugate to demonstrate an improvement in overall survival in advanced or recurrent endometrial cancer in this setting compared with chemotherapy in a global Phase 3 study.
The incidence and mortality rates of endometrial cancer are rising worldwide, and the results of TroFuse-005 have the potential to change how we treat patients who have received previous chemotherapy and immunotherapy.